aTyr Pharma (ATYR) Competitors

$0.40 -0.13 (-25.33%)

Closing price 05/13/2026 04:00 PM Eastern

Extended Trading

$0.41 +0.02 (+4.07%)

As of 04:15 AM Eastern

ATYR vs. SNDL, OVID, IRD, SOPH, and SIGA

Should you buy aTyr Pharma stock or one of its competitors? MarketBeat compares aTyr Pharma with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with aTyr Pharma include SNDL (SNDL), Ovid Therapeutics (OVID), Opus Genetics (IRD), SOPHiA GENETICS (SOPH), and Siga Technologies (SIGA). These companies are all part of the "pharmaceutical products" industry.

How does aTyr Pharma compare to SNDL?

aTyr Pharma (NASDAQ:ATYR) and SNDL (NASDAQ:SNDL) are both small-cap medical companies, but which is the better stock? We will compare the two businesses based on the strength of their institutional ownership, analyst recommendations, profitability, earnings, media sentiment, valuation, risk and dividends.

aTyr Pharma presently has a consensus price target of $25.67, suggesting a potential upside of 6,383.12%. SNDL has a consensus price target of $5.00, suggesting a potential upside of 254.61%. Given aTyr Pharma's stronger consensus rating and higher probable upside, equities research analysts clearly believe aTyr Pharma is more favorable than SNDL.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
aTyr Pharma	1 Sell rating(s)	5 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00
SNDL	2 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	1.67

61.7% of aTyr Pharma shares are owned by institutional investors. 5.8% of aTyr Pharma shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.

SNDL has higher revenue and earnings than aTyr Pharma. SNDL is trading at a lower price-to-earnings ratio than aTyr Pharma, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
aTyr Pharma	$190K	204.31	-$74.12M	-$0.79	N/A
SNDL	$677.32M	0.54	-$11.29M	-$0.03	N/A

aTyr Pharma has a beta of 0.66, indicating that its stock price is 34% less volatile than the broader market. Comparatively, SNDL has a beta of 0.88, indicating that its stock price is 12% less volatile than the broader market.

In the previous week, aTyr Pharma had 8 more articles in the media than SNDL. MarketBeat recorded 9 mentions for aTyr Pharma and 1 mentions for SNDL. aTyr Pharma's average media sentiment score of 0.22 beat SNDL's score of -0.07 indicating that aTyr Pharma is being referred to more favorably in the media.

Company	Overall Sentiment
aTyr Pharma	Neutral
SNDL	Neutral

aTyr Pharma has a net margin of 0.00% compared to SNDL's net margin of -1.19%. SNDL's return on equity of -1.02% beat aTyr Pharma's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
aTyr Pharma	N/A	-99.87%	-74.41%
SNDL	-1.19%	-1.02%	-0.85%

Summary

aTyr Pharma beats SNDL on 9 of the 15 factors compared between the two stocks.

How does aTyr Pharma compare to Ovid Therapeutics?

Ovid Therapeutics (NASDAQ:OVID) and aTyr Pharma (NASDAQ:ATYR) are both small-cap medical companies, but which is the better investment? We will compare the two companies based on the strength of their media sentiment, analyst recommendations, valuation, dividends, profitability, earnings, institutional ownership and risk.

Ovid Therapeutics currently has a consensus price target of $4.63, suggesting a potential upside of 65.18%. aTyr Pharma has a consensus price target of $25.67, suggesting a potential upside of 6,383.12%. Given aTyr Pharma's higher possible upside, analysts plainly believe aTyr Pharma is more favorable than Ovid Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Ovid Therapeutics	1 Sell rating(s)	0 Hold rating(s)	7 Buy rating(s)	1 Strong Buy rating(s)	2.89
aTyr Pharma	1 Sell rating(s)	5 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00

72.2% of Ovid Therapeutics shares are held by institutional investors. Comparatively, 61.7% of aTyr Pharma shares are held by institutional investors. 13.1% of Ovid Therapeutics shares are held by company insiders. Comparatively, 5.8% of aTyr Pharma shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.

Ovid Therapeutics has higher revenue and earnings than aTyr Pharma. Ovid Therapeutics is trading at a lower price-to-earnings ratio than aTyr Pharma, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Ovid Therapeutics	$7.25M	50.93	-$17.41M	-$0.31	N/A
aTyr Pharma	$190K	204.31	-$74.12M	-$0.79	N/A

Ovid Therapeutics has a beta of 0.18, meaning that its stock price is 82% less volatile than the broader market. Comparatively, aTyr Pharma has a beta of 0.66, meaning that its stock price is 34% less volatile than the broader market.

In the previous week, aTyr Pharma had 4 more articles in the media than Ovid Therapeutics. MarketBeat recorded 9 mentions for aTyr Pharma and 5 mentions for Ovid Therapeutics. Ovid Therapeutics' average media sentiment score of 1.10 beat aTyr Pharma's score of 0.22 indicating that Ovid Therapeutics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Ovid Therapeutics	1 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
aTyr Pharma	0 Very Positive mention(s)	0 Positive mention(s)	7 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Neutral

aTyr Pharma has a net margin of 0.00% compared to Ovid Therapeutics' net margin of -240.11%. Ovid Therapeutics' return on equity of -31.36% beat aTyr Pharma's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Ovid Therapeutics	-240.11%	-31.36%	-24.81%
aTyr Pharma	N/A	-99.87%	-74.41%

Summary

Ovid Therapeutics beats aTyr Pharma on 11 of the 17 factors compared between the two stocks.

How does aTyr Pharma compare to Opus Genetics?

Opus Genetics (NASDAQ:IRD) and aTyr Pharma (NASDAQ:ATYR) are both small-cap medical companies, but which is the better investment? We will compare the two companies based on the strength of their media sentiment, analyst recommendations, valuation, dividends, profitability, earnings, institutional ownership and risk.

aTyr Pharma has a net margin of 0.00% compared to Opus Genetics' net margin of -892.36%. aTyr Pharma's return on equity of -99.87% beat Opus Genetics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Opus Genetics	-892.36%	-709.20%	-220.01%
aTyr Pharma	N/A	-99.87%	-74.41%

Opus Genetics has a beta of 0.62, meaning that its stock price is 38% less volatile than the broader market. Comparatively, aTyr Pharma has a beta of 0.66, meaning that its stock price is 34% less volatile than the broader market.

Opus Genetics has higher revenue and earnings than aTyr Pharma. Opus Genetics is trading at a lower price-to-earnings ratio than aTyr Pharma, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Opus Genetics	$14.20M	25.29	-$49.59M	-$0.82	N/A
aTyr Pharma	$190K	204.31	-$74.12M	-$0.79	N/A

Opus Genetics currently has a consensus price target of $10.20, suggesting a potential upside of 102.78%. aTyr Pharma has a consensus price target of $25.67, suggesting a potential upside of 6,383.12%. Given aTyr Pharma's higher possible upside, analysts plainly believe aTyr Pharma is more favorable than Opus Genetics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Opus Genetics	1 Sell rating(s)	0 Hold rating(s)	11 Buy rating(s)	1 Strong Buy rating(s)	2.92
aTyr Pharma	1 Sell rating(s)	5 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00

15.0% of Opus Genetics shares are held by institutional investors. Comparatively, 61.7% of aTyr Pharma shares are held by institutional investors. 11.7% of Opus Genetics shares are held by company insiders. Comparatively, 5.8% of aTyr Pharma shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.

In the previous week, Opus Genetics had 5 more articles in the media than aTyr Pharma. MarketBeat recorded 14 mentions for Opus Genetics and 9 mentions for aTyr Pharma. aTyr Pharma's average media sentiment score of 0.22 beat Opus Genetics' score of -0.36 indicating that aTyr Pharma is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Opus Genetics	0 Very Positive mention(s)	0 Positive mention(s)	7 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
aTyr Pharma	0 Very Positive mention(s)	0 Positive mention(s)	7 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Neutral

Summary

aTyr Pharma beats Opus Genetics on 10 of the 17 factors compared between the two stocks.

How does aTyr Pharma compare to SOPHiA GENETICS?

SOPHiA GENETICS (NASDAQ:SOPH) and aTyr Pharma (NASDAQ:ATYR) are both small-cap medical companies, but which is the superior business? We will contrast the two companies based on the strength of their media sentiment, valuation, analyst recommendations, profitability, risk, earnings, dividends and institutional ownership.

aTyr Pharma has a net margin of 0.00% compared to SOPHiA GENETICS's net margin of -44.48%. SOPHiA GENETICS's return on equity of -62.74% beat aTyr Pharma's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
SOPHiA GENETICS	-44.48%	-62.74%	-21.85%
aTyr Pharma	N/A	-99.87%	-74.41%

SOPHiA GENETICS has a beta of 1.01, meaning that its share price is 1% more volatile than the broader market. Comparatively, aTyr Pharma has a beta of 0.66, meaning that its share price is 34% less volatile than the broader market.

aTyr Pharma has lower revenue, but higher earnings than SOPHiA GENETICS. SOPHiA GENETICS is trading at a lower price-to-earnings ratio than aTyr Pharma, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
SOPHiA GENETICS	$77.27M	4.00	-$79M	-$0.52	N/A
aTyr Pharma	$190K	204.31	-$74.12M	-$0.79	N/A

SOPHiA GENETICS currently has a consensus price target of $7.50, suggesting a potential upside of 66.30%. aTyr Pharma has a consensus price target of $25.67, suggesting a potential upside of 6,383.12%. Given aTyr Pharma's higher possible upside, analysts clearly believe aTyr Pharma is more favorable than SOPHiA GENETICS.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
SOPHiA GENETICS	1 Sell rating(s)	0 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.33
aTyr Pharma	1 Sell rating(s)	5 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00

31.6% of SOPHiA GENETICS shares are owned by institutional investors. Comparatively, 61.7% of aTyr Pharma shares are owned by institutional investors. 4.9% of SOPHiA GENETICS shares are owned by company insiders. Comparatively, 5.8% of aTyr Pharma shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.

In the previous week, aTyr Pharma had 5 more articles in the media than SOPHiA GENETICS. MarketBeat recorded 9 mentions for aTyr Pharma and 4 mentions for SOPHiA GENETICS. SOPHiA GENETICS's average media sentiment score of 0.31 beat aTyr Pharma's score of 0.22 indicating that SOPHiA GENETICS is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
SOPHiA GENETICS	0 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
aTyr Pharma	0 Very Positive mention(s)	0 Positive mention(s)	7 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Neutral

Summary

SOPHiA GENETICS and aTyr Pharma tied by winning 8 of the 16 factors compared between the two stocks.

How does aTyr Pharma compare to Siga Technologies?

Siga Technologies (NASDAQ:SIGA) and aTyr Pharma (NASDAQ:ATYR) are both small-cap medical companies, but which is the superior business? We will contrast the two companies based on the strength of their media sentiment, valuation, analyst recommendations, profitability, risk, earnings, dividends and institutional ownership.

In the previous week, Siga Technologies and Siga Technologies both had 9 articles in the media. Siga Technologies' average media sentiment score of 0.36 beat aTyr Pharma's score of 0.22 indicating that Siga Technologies is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Siga Technologies	0 Very Positive mention(s)	0 Positive mention(s)	5 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Neutral
aTyr Pharma	0 Very Positive mention(s)	0 Positive mention(s)	7 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Neutral

55.4% of Siga Technologies shares are owned by institutional investors. Comparatively, 61.7% of aTyr Pharma shares are owned by institutional investors. 2.7% of Siga Technologies shares are owned by company insiders. Comparatively, 5.8% of aTyr Pharma shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.

Siga Technologies has a net margin of 21.58% compared to aTyr Pharma's net margin of 0.00%. Siga Technologies' return on equity of 10.60% beat aTyr Pharma's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Siga Technologies	21.58%	10.60%	8.94%
aTyr Pharma	N/A	-99.87%	-74.41%

Siga Technologies has a beta of 0.93, meaning that its share price is 7% less volatile than the broader market. Comparatively, aTyr Pharma has a beta of 0.66, meaning that its share price is 34% less volatile than the broader market.

Siga Technologies has higher revenue and earnings than aTyr Pharma. aTyr Pharma is trading at a lower price-to-earnings ratio than Siga Technologies, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Siga Technologies	$94.57M	3.27	$23.28M	$0.27	15.96
aTyr Pharma	$190K	204.31	-$74.12M	-$0.79	N/A

aTyr Pharma has a consensus price target of $25.67, suggesting a potential upside of 6,383.12%. Given aTyr Pharma's higher possible upside, analysts clearly believe aTyr Pharma is more favorable than Siga Technologies.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Siga Technologies	0 Sell rating(s)	1 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	2.00
aTyr Pharma	1 Sell rating(s)	5 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00

Summary

Siga Technologies beats aTyr Pharma on 9 of the 14 factors compared between the two stocks.

Get aTyr Pharma News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding ATYR and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

ATYR vs. The Competition

Export

Metric	aTyr Pharma	MED Industry	Medical Sector	NASDAQ Exchange
Market Cap	$51.99M	$3.42B	$6.30B	$12.20B
Dividend Yield	N/A	2.30%	2.79%	5.30%
P/E Ratio	-0.50	18.52	21.00	25.58
Price / Sales	204.31	301.14	554.55	78.84
Price / Cash	N/A	122.51	42.94	55.34
Price / Book	0.57	6.75	9.75	6.66
Net Income	-$74.12M	$24.11M	$3.55B	$333.63M
7 Day Performance	-57.05%	-0.53%	-0.53%	-0.11%
1 Month Performance	-52.92%	0.34%	1.20%	3.94%
1 Year Performance	-86.93%	78.62%	41.22%	36.07%

aTyr Pharma Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
ATYR aTyr Pharma	2.1756 of 5 stars	$0.40 -25.3%	$25.67 +6,383.1%	-88.0%	$51.99M	$190K	N/A	53	News Coverage Gap Up High Trading Volume
SNDL SNDL	3.1602 of 5 stars	$1.43 -0.3%	$5.00 +249.7%	+6.8%	$369.36M	$677.32M	N/A	2,751
OVID Ovid Therapeutics	2.7447 of 5 stars	$2.79 -0.4%	$4.63 +65.8%	+879.0%	$369.25M	$7.25M	N/A	60	Positive News Earnings Report
IRD Opus Genetics	2.7458 of 5 stars	$5.12 +2.6%	$10.30 +101.2%	+424.4%	$356.30M	$14.20M	N/A	14	Trending News Earnings Report Upcoming Earnings Analyst Forecast Analyst Revision
SOPH SOPHiA GENETICS	2.6106 of 5 stars	$4.79 -7.0%	$7.50 +56.6%	+44.6%	$352.70M	$77.27M	N/A	520	Gap Down High Trading Volume

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:ATYR) was last updated on 5/14/2026 by MarketBeat.com Staff.

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

aTyr Pharma (ATYR) Competitors

ATYR vs. SNDL, OVID, IRD, SOPH, and SIGA

How does aTyr Pharma compare to SNDL?

Summary

How does aTyr Pharma compare to Ovid Therapeutics?

Summary

How does aTyr Pharma compare to Opus Genetics?

Summary

How does aTyr Pharma compare to SOPHiA GENETICS?

Summary

How does aTyr Pharma compare to Siga Technologies?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

ATYR vs. The Competition

aTyr Pharma Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

aTyr Pharma (ATYR) Competitors

ATYR vs. SNDL, OVID, IRD, SOPH, and SIGA

How does aTyr Pharma compare to SNDL?

Do analysts recommend ATYR or SNDL?

Do insiders & institutionals have more ownership in ATYR or SNDL?

Which has stronger valuation and earnings, ATYR or SNDL?

Which has more volatility and risk, ATYR or SNDL?

Does the media prefer ATYR or SNDL?

Is ATYR or SNDL more profitable?

Summary

How does aTyr Pharma compare to Ovid Therapeutics?

Do analysts rate OVID or ATYR?

Do institutionals & insiders hold more shares of OVID or ATYR?

Which has preferable earnings & valuation, OVID or ATYR?

Which has more volatility and risk, OVID or ATYR?

Does the media favor OVID or ATYR?

Is OVID or ATYR more profitable?

Summary

How does aTyr Pharma compare to Opus Genetics?

Is IRD or ATYR more profitable?

Which has more volatility and risk, IRD or ATYR?

Which has preferable earnings & valuation, IRD or ATYR?

Do analysts rate IRD or ATYR?

Do institutionals & insiders hold more shares of IRD or ATYR?

Does the media favor IRD or ATYR?

Summary

How does aTyr Pharma compare to SOPHiA GENETICS?

Is SOPH or ATYR more profitable?

Which has more risk and volatility, SOPH or ATYR?

Which has higher earnings and valuation, SOPH or ATYR?

Do analysts recommend SOPH or ATYR?

Do insiders and institutionals hold more shares of SOPH or ATYR?

Does the media refer more to SOPH or ATYR?

Summary

How does aTyr Pharma compare to Siga Technologies?

Does the media refer more to SIGA or ATYR?

Do insiders and institutionals hold more shares of SIGA or ATYR?

Is SIGA or ATYR more profitable?

Which has more risk and volatility, SIGA or ATYR?

Which has higher earnings and valuation, SIGA or ATYR?

Do analysts recommend SIGA or ATYR?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

ATYR vs. The Competition

aTyr Pharma Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools